Research Article Details
| Article ID: | A13480 |
| PMID: | 29956203 |
| Source: | Adv Exp Med Biol |
| Title: | Epidemiology and Etiologic Associations of Non-alcoholic Fatty Liver Disease and Associated HCC. |
| Abstract: | Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world and will soon become the number one cause of hepatocellular carcinoma (HCC), liver transplantation and liver-related mortality. The disease often occurs in the setting of metabolic conditions such as obesity and type II diabetes mellitus. These same metabolic drivers are also risk factors for NAFLD associated HCC which can occur even in the absence of cirrhosis or advanced fibrosis and appears to be phenotypically different to HCCs arising from other chronic liver diseases. The frequencies of liver-related events and HCC among NAFLD patients is low, especially when compared to cardiovascular disease and extrahepatic malignancies. However, the large denominator of total patients affected with NAFLD means that these events will impose an enormous clinical and economic burden on our society. Moreover, this burden is expected to rise further in the future. Therefore, the global NAFLD epidemic has arrived at our doorstep and demands our attention. |
| DOI: | 10.1007/978-981-10-8684-7_2 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S10 | Liver transplantation | -- | -- | -- | Details |
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D545 | Pig placenta extract | Biological extract | -- | -- | -- | Under clinical trials | Details |
| D316 | S-adenosyl-L-methionine | Chemical drug | DB00118 | GNMT cofactor | Antiviral | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |